Island Pharmaceuticals: Appoints Sofgen for one-off supply of ISLA-101

Island Pharmaceuticals Appoints Sofgen for one-off supply of ISLA-101

  • Island Pharmaceuticals (ILA) executes a one-off proposal with Sofgen for the manufacture of ISLA-101 for the upcoming Phase 2a PEACH clinical trial in dengue infected subjects
  • The new proposal contains a schedule that has ISLA-101 clinical material being manufactured in mid-August, a six-week delay from most recent estimates
  • The company was looking for alternative manufacturers after its prior manufacturer was unable to provide certainty required to plan effectively
  • The new timeline has been consolidated and the company expects the investigational new drug (IND) application to be filed in October with the trial commencing in November
  • Shares in Island Pharmaceuticals are down 18.8 per cent, trading at 13 cents as of 12:01 pm AEST
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Spektr Strengthens Compliance Efforts with $20M Funding

Fintech startup Spektr secures $20 million for AI-driven compliance solutions.Highlights: Spektr raises $20 million to enhance its AI...

Hacked DeFi Platform Drift Secures Funds to Repay Customers

Drift plans to relaunch with Tether support after addressing security issues.Highlights: Drift DeFi platform has secured funds after...

Business Banking Fintech Slash Reaches Unicorn Status

The fintech startup achieves a valuation of over $1 billion.Highlights: Slash has been valued at over $1 billion.The...

Amex Strengthens Digital Services with AI Expense Management Acquisition

American Express to acquire Hyper to enhance its business offerings.Highlights: American Express announces the acquisition of AI startup...